Black Diamond Therapeutic Q2 2024 GAAP EPS $(0.36) Misses $(0.35) Estimate
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutics reported a Q2 2024 GAAP EPS of $(0.36), missing the estimate of $(0.35).
August 06, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Black Diamond Therapeutics reported a Q2 2024 GAAP EPS of $(0.36), which is below the estimated $(0.35). This miss could lead to a negative short-term impact on the stock price as it indicates the company is not meeting earnings expectations.
The earnings per share (EPS) miss, even by a small margin, can negatively affect investor sentiment and lead to a short-term decline in the stock price. Investors often react to earnings misses by selling off shares, which can drive the price down.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100